Ascendis Pharma (ASND) announced that YORVIPATH is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone, administered once-daily, designed to provide continuous exposure to active PTH over the 24-hour dosing period.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk
- Ascendis Pharma announces results from New InsiGHTS tril of TransCon hGH
- Closing Bell Movers: RH soars 20% on earnings, guidance raise
- Ascendis Pharma’s TransCon hGH Receives FDA Review for Adult Use
- Ascendis Pharma announces FDA to review TransCon hGH sBLA
Questions or Comments about the article? Write to editor@tipranks.com